^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 695502 (bevacizumab biosimilar)

    i
    Associations
    News

    Trials

    Company:
    Boehringer Ingelheim
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer (NCT02272413)
    Phase 3
    Boehringer Ingelheim
    Completed
    Last update posted :
    01/13/2020
    Initiation :
    07/08/2015
    Primary completion :
    06/30/2017
    Completion :
    11/16/2018
    EGFR • ALK
    |
    ALK mutation
    |
    BI 695502 (bevacizumab biosimilar)